Discussions

What the story of fluoxetine ultimately suggests is something humbling about pharmacology: that we rarely understand our medicines as fully as we believe we do at the moment we approve them.

Fluoxetine was designed to treat depression. It works for depression. But it also turned out to work for OCD, for bulimia, probably for PTSD, possibly for stroke recovery, plausibly for certain cancers, and perhaps for some of the most feared neurodegenerative diseases of aging. Each of these findings has come not from designing a new molecule but from listening more carefully to an old one.

There is a broader lesson here for drug development, which has trended heavily toward expensive, narrowly targeted biologics and gene therapies. Those approaches have genuine and profound value. But the repurposing of existing small molecules — cheap, off-patent, globally available drugs whose safety profiles are already established — represents an underinvested frontier. If fluoxetine has this much left to teach us, the question is not only what else it can do, but how many other molecules on pharmacy shelves are quietly waiting to be rediscovered.

The most versatile molecule in medicine did not arrive in a flash of futuristic ingenuity. It arrived in a small green-and-white capsule in 1987, and it is still, nearly four decades later, surprising us.